The following resolutions were passed at the Annual General Meeting (the “AGM”) of BICO Group AB (publ) (“BICO” or the “Company”) held today on 26 April 2022 in Gothenburg, Sweden.

Adoption of Income Statement and Balance Sheet for the Financial Year 2021 and Discharge from Liability

The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2021 as well as the balance sheet and the consolidated balance sheet as of 31 December 2021, as set out in the annual report. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2021.

Allocation of Profits

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend be paid for 2021 and that the profits available to the AGM shall be carried forward.

Election of Board Members, Auditors, Fees to the Board of Directors and Auditors

The AGM resolved, in accordance with the Nomination Committee’s proposal, that the number of members of the Board of Directors shall be eight without deputies and that the number of auditors shall be one registered accounting firm.

In accordance with the Nomination Committee’s proposal, Carsten Browall, Bengt Sjöholm, Christian Wildmoser, Erik Gatenholm, Helena Skåntorp and Susan Tousi were re-elected as members of the Board of Directors. Further, Rolf Classon and Ulrika Dellby were elected new members of the Board of Directors in accordance with the Nomination Committee’s proposal. All elections for the period until the end of the next Annual General Meeting. Carsten Browall was re-elected as the Chairman of the Board of Directors. The registered audit firm Deloitte AB was re-elected as auditor of the Company, with Fredrik Jonsson as auditor-in-charge, for the period until the end of the next Annual General Meeting.

The AGM further resolved to, in accordance with the Nomination Committee’s proposal, that fees to members of the Board shall be paid with SEK 600,000 to the Chairman of the Board, SEK 250,000 to each of the other members of the Board, SEK 100,000 to the Chairman of the Audit Committee, SEK 50,000 to each of the other members of the Audit Committee, SEK 60,000 to the Chairman of the Remuneration Committee, and SEK 35,000 to each of the other members of the Remuneration Committee. The AGM further resolved, in accordance with the Nomination Committee’s proposal, that the remuneration to the auditor shall be paid in accordance with approved statement of costs.

Approval of the Board’s remuneration report

The AGM resolved, in accordance with the Board of Directors’ proposal, to approve the Remuneration Report for the financial year 2021 that has been prepared by the Board of Directors.

Authorization for the Board of Directors to resolve on new share issues

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, at one or several occasions for the period until end of the next AGM, resolve on new share issues equal to no more than 10 per cent of the, at the time of the issue resolution, registered share capital of the Company.

For further information, please contact:
Avijit Minocha, Head of Marketing

Phone (US): +1 (617) 637 5372
Email: akm@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on April, 26, 2022 at 22:30 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.

The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.  

The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com

Contact us!

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.